Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO and managing director Nina Webster chats with Proactive live from the ASX Small and Mid Cap Conference in March 2024..
Guess which ASX healthcare stock is rocketing 20% today fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.
Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics MarketThe global focal segmentmental glomerulosclerosis (FSGS) treatments market sales is expected to expand at a compound annual growth rate (CAGR) of 5% between 2023 and 2033, from US$ 3 billion in 2023 to US$ 4.89 billion by 2033. From 2018 to 2022, Focal Seg.